Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Sep;38(9):1066-70.
doi: 10.1038/ng1857. Epub 2006 Jul 30.

Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy

Mani S Mahadevan  1 , Ramesh S Yadava, Qing Yu, Sadguna Balijepalli, Carla D Frenzel-McCardell, T David Bourne, Lawrence H Phillips
Affiliations
Comparative Study

Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy

Mani S Mahadevan et al. Nat Genet. 2006 Sep.

Abstract

Myotonic dystrophy (DM1), the most common muscular dystrophy in adults, is caused by an expanded (CTG)n tract in the 3' UTR of the gene encoding myotonic dystrophy protein kinase (DMPK), which results in nuclear entrapment of the 'toxic' mutant RNA and interacting RNA-binding proteins (such as MBNL1) in ribonuclear inclusions. It is unclear if therapy aimed at eliminating the toxin would be beneficial. To address this, we generated transgenic mice expressing the DMPK 3' UTR as part of an inducible RNA transcript encoding green fluorescent protein (GFP). We were surprised to find that mice overexpressing a normal DMPK 3' UTR mRNA reproduced cardinal features of myotonic dystrophy, including myotonia, cardiac conduction abnormalities, histopathology and RNA splicing defects in the absence of detectable nuclear inclusions. However, we observed increased levels of CUG-binding protein (CUG-BP1) in skeletal muscle, as seen in individuals with DM1. Notably, these effects were reversible in both mature skeletal and cardiac muscles by silencing transgene expression. These results represent the first in vivo proof of principle for a therapeutic strategy for treatment of myotonic dystrophy by ablating or silencing expression of the toxic RNA molecules.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS STATEMENT

The authors declare that they have no competing financial interests.

Figures

Figure 1
Figure 1
Transgene expression. (a) Transgenes used to create double transgenic tetracycline-inducible mice. (b) RNA-FISH and fluorescence microscopy of skeletal muscle in mice in which transgene expression was induced demonstrates GFP expression in all mice and RNA foci only in mice expressing the GFP-DMPK 3′ UTR (CTG)200. (c) RNA blot of skeletal muscle RNA showing significant transgene induction in (CTG)5 mice relative to endogenous Dmpk expression. Gapdh was used as loading control. (d) RNA-FISH and immunofluorescence for MBNL1 demonstrating colocalization in (CTG)200 mice. (e) Antibodies to MBNL1 show that wild-type mice (FVB) and (CTG)5 mice have diffuse nuclear staining, whereas (CTG)200 mice have distinct MBNL foci.
Figure 2
Figure 2
Myotonic dystrophy phenotypes in transgenic mice. (a) Electromyography in skeletal muscles of mice in which transgene expression was not induced (‘No doxy’) shows a quiet baseline and classic myotonia in mice in which transgene expression was induced (‘Doxy’). ClC-1 immunohistochemistry showing normal sarcolemmal pattern of ClC-1 and loss of ClC-1 in myotonic mice. (b) Progressive cardiac conduction disturbances detected by serial ECGs on transgenic mice in which transgene expression was induced PR interval (PR int.) is prolonged by day 3. Note irregular and dropped beats by day 5 and lack of P waves by day 8. (c) Clcn1 and Tnnt3 RNA splicing abnormalities in skeletal muscle of mice in which transgene expression was induced. Lane 1: DNA marker; lane 2: wild-type; lane 3: uninduced 5-313; lane 4: induced 5-313. Note increased amounts of larger splice products. (d) H&E staining of skeletal muscle demonstrating increased numbers of central nuclei, fiber size variation and nuclear clumping in mice in which transgene expression was induced.
Figure 3
Figure 3
Reversal of RNA toxicity. (a) ClC-1 immunohistochemistry shows loss of ClC-1 in mice in which transgene expression was induced and reversion to normal patterns with transgene silencing. (b) ECGs demonstrating examples of first-degree heart block (prolonged PR interval) in mice in which transgene expression was induced. Mouse #3074 reverted to normal from first-degree heart block. Mouse #2090 had second-degree heart block (Wenkebach-type) refractory to reversal (* indicates dropped beat). (c) Clcn1 and Tnnt3 RNA splicing abnormalities in skeletal muscle were reversed. Lanes 1,2: uninduced; lanes 3,4: induced; lanes 5,6: mice that reverted. (d) H&E staining of skeletal muscle showing reversal of histopathology. Mice reverted for over two months. Note obvious reductions in small fibers, central nuclei and nuclear clumping in mice that have reverted.
Figure 4
Figure 4
CUG-BP1 levels elevated by toxic RNA. Protein blots showing expression of CUG-BP1, MBNL1 and GFP in mouse skeletal muscle and heart. GAPDH was used as a loading control. Note induction of CUB-BP1 in skeletal muscle and reversion with transgene silencing. Also, there was no change in MBNL1 expression in mouse tissues in which transgene expression was induced. The 5-313 mice used in this figure had been induced continuously for over 10 months, and tissues from mice that reverted were collected within 20 d after stopping doxycycline.
See this image and copyright information in PMC

Comment in

  • Reversal of fortune.
    Timchenko L. Timchenko L. Nat Genet. 2006 Sep;38(9):976-7. doi: 10.1038/ng0906-976. Nat Genet. 2006. PMID: 16941004 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mahadevan M, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science. 1992;255:1253–1255. - PubMed
    1. Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord. 2005;15:5–16. - PubMed
    1. Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol. 1995;128:995–1002. - PMC - PubMed
    1. Davis BM, McCurrach ME, Taneja KL, Singer RH, Housman DE. Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci USA. 1997;94:7388–7393. - PMC - PubMed
    1. Amack JD, Paguio AP, Mahadevan MS. Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum Mol Genet. 1999;8:1975–1984. - PubMed

Publication types

MeSH terms